Bryan J. Luchs

Partner, New York



A partner in the Firm's Mergers & Acquisitions Group based in New York, Bryan Luchs is an experienced mergers and acquisitions lawyer.

He offers clients the benefit of his knowledge and experience in a diverse range of industries, and his particularly extensive track record in the pharmaceuticals and biotechnology sectors.

Bryan is listed as a "Leading Lawyer" for M&A in the United States by Euromoney (2021).

Acting on behalf of acquirers, targets, boards of directors, special committees, investors and investment banks, Bryan engages in complex domestic and cross-border deals, both negotiated and unsolicited, and in public and private transactions.

Bars and Courts
New York
University of Pennsylvania
University of Pennsylvania Law School
Pepperdine University


Recent matters include the representation of:

  • Falcon Capital Acquisition Corp. (NASDAQ: FCAC), a SPAC, in its US$3.9 billion business combination with Sharecare, Inc., a digital health company based in Georgia.
  • InterPrivate III Financial Partners Inc. (NYSE: IPVF), a SPAC, in its US$2.3 billion acquisition of Aspiration Partners, Inc., a global leader in Sustainability as a Service solutions for consumers and companies.
  • DFP Healthcare Acquisitions Corp. (NASDAQ: DFPH, DFPHW), a SPAC, in its US$842 million business combination with The Oncology Institute, a US market-leader in value-based oncology care.
  • Deerfield Healthcare Technology Acquisitions Corp. (NASDAQ: DFHT), a SPAC, in its US$614 million business combination with CareMax Medical Group, L.L.C. and IMC Medical Group Holdings LLC, creating a technology-enabled care platform providing value-based care and chronic disease management to seniors.
  • FS Development Corp. II (NASDAQ: FSII), a SPAC, in its US$276.2 million business combination with Pardes Biosciences, Inc., an early stage biopharmaceutical company developing a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
  • Helix Acquisition Corp. (NASDAQ: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases.
  • FS Development Corp. (NASDAQ: FSDC), a SPAC, in its US$216 million business combination with Gemini Therapeutics, Inc., a clinical stage precision medicine company developing treatments for genetically defined age-related macular degeneration.
  • Lantheus Holdings, Inc. (NASDAQ: LNTH) in its acquisition of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX).
  • Roche Diagnostics Corp. in the sale of Roche Health Solutions Inc. to CardioNet, LLC, a wholly owned subsidiary of BioTelemetry, Inc.
  • Hikma Pharmaceuticals PLC in its US$2.65 billion acquisition of the US-based generic drugs businesses, Roxane Laboratories and Boehringer Ingelheim Roxane, from German drug maker Boehringer Ingelheim.
  • Hikma Pharmaceuticals PLC in its acquisition of assets relating to a portfolio of six injectable products for commercialization in certain European markets from Pfizer.
  • Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a world leader in musculoskeletal health solutions, in its US$14 billion deal to acquire Biomet, Inc., one of the world's leading medical device manufacturers.
  • Omnicare, Inc. in its US$12.7 billion acquisition by CVS Health, as well as Omnicare's prior US$1.8 billion unsolicited acquisition of NeighborCare Inc. and US$460 million unsolicited acquisition of NCS HealthCare, Inc.
  • Sony Corporation of America in its US$2.2 billion acquisition of EMI Music Publishing with a consortium of acquirors; acquisition of the 50% interest in Sony/ATV Music Publishing LLC held by the Estate of Michael Jackson.
  • King Pharmaceuticals, Inc. in its US$1.6 billion unsolicited acquisition of Alpharma Inc.
  • Roivant Sciences Ltd. on several portfolio company transactions.
  • Certares LP, a private equity group with a focus in the travel, transportation and hospitality industry, in the acquisition of 50 percent of the equity of AmaWaterways, a premium European river cruise operator; and in its acquisition of Guardian Alarm, a super-regional security provider.
  • Special Committee of the Board of Directors of GFI Group Inc., (NYSE: GFIG), the New York brokerage and clearing house, in the successful completion of a tender offer by BGC Partners, Inc. (NASDAQ: BGCP), a leading global brokerage company servicing the financial and real estate markets, for the outstanding shares of GFI, resulting in an equity value of approximately US$780 million and an enterprise value of US$1 billion. The transaction marks one of the most complex hostile M&A transactions.
  • J.F. Hillebrand USA Holding, Inc., a portfolio company of Cobepa SA (the Belgian investment company), in its acquisition of a majority of the outstanding equity interests of Satellite Logistics Group, a leading beverage supply chain logistics business.
  • Nordic Capital, DLJ Merchant Banking, Avista Capital and other private equity sponsors in their US$1.525 billion sale of Fougera Pharmaceuticals to Sandoz.
  • Nestlé México, SA de CV in its acquisition of a majority stake in Terrafertil, a company selling natural, organic, plant-based foods and healthy snacks.
Awards and Recognition

Leading Lawyer for M&A in the United States, Euromoney, 2021